What we’ve seen since the February 19 top in growth stocks has basically been a rolling crash, with most every leading stock from 2024 breaking its intermediate-term uptrend. Now, short-term, we do think things are finally getting hairy—recession fears and tariff headlines are making the rounds even as we are seeing a few near-term rays of light (the number of stocks hitting new lows is actually drying up a bit). That might be a reason to hold a some smaller positions at a profit, but overall, we remain clearly defensive. Our Market Monitor is now at a level 3, though we’re most interested in seeing how strong and persistent any bounce is once it begins.
This week’s list has names from all over the map, though medical and foreign stocks certainly dominate the list. Our Top Pick is a mid-cap biotech that has booming sales and earnings, and the stock is strong.